healio.com
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans and access issues.
Adults and pediatric patients with Crohn’s, caregivers, clinicians prescribing IBD therapies, and patients already on biologics or oral therapies concerned about treatment choices and approvals.
What To Know
This short Healio video transcript summarizes treatment options currently used in Crohn’s disease.
It lists longstanding biologic options (anti-TNFs infliximab, adalimumab, certolizumab), vedolizumab, ustekinumab (Stelara), newer IL-23–targeting agents (risankizumab, mirikizumab, guselkumab), and the JAK inhibitor upadacitinib as the first oral FDA‑approved therapy for Crohn’s.
The piece is a brief overview and does not provide study data or specific guidance. The video is an expert perspective noting that multiple classes of medications are available for Crohn’s, including injectable biologics and an oral JAK inhibitor. It mentions recent approvals in the IL‑23 drug class and names several branded and generic agents.
It also points viewers to related videos on response predictors, head‑to‑head trials, cost/access issues, and pediatric considerations. If you want more detail: watch the full Healio video or read linked pieces for discussion of comparative effectiveness, predictors of response, costs, and pediatric management.
This transcript is an overview rather than an in‑depth review.
The content is a brief expert commentary (automatically transcribed) and does not report trial results or comparative data. It names therapies and classes but does not provide efficacy, safety, or prescribing details. For treatment decisions, consult a clinician and original study or guideline sources.
